UCB 슬롯 사이트 슬롯사이트 Unveils the First Dual IL-17A and IL-17F Inhibitor, Highlighting Unmet Needs and Promising Clinical Outcomes
UCB Korea has introduced Bimzelx (active ingredient: bimekizumab), Korea's first dual inhibitor targeting interleukin-17A (IL-17A) and interleukin-17F (IL-17F), as a potential game-changer for plaque 슬롯 사이트 슬롯사이트, a chronic inflammatory condition. Approved on August 29, the drug was the centerpiece of a November 20th media session addressing Korea’s treatment landscape, unmet needs, and clinical outcomes.
Bimzelx is the only treatment in Korea capable of simultaneously inhibiting IL-17A and IL-17F, cytokines critical to 슬롯 사이트 슬롯사이트 pathogenesis. IL-17F levels in psoriatic lesions can be up to 30 times higher than IL-17A, making dual inhibition a promising strategy.
Professor Gi-heon Jung of Kyung Hee University Hospital’s Dermatology Department explained, “슬롯 사이트 슬롯사이트 is not just a skin disease but a systemic condition driven by immune dysfunction. Its treatment demands lifelong management aimed at minimizing side effects, alleviating symptoms, preventing relapses, and improving patients' quality of life.” He also highlighted challenges in treating areas like the scalp, nails, palms, and genitals, where residual lesions significantly affect daily life.
Professor Jung emphasized the broader impact of 슬롯 사이트 슬롯사이트, likening the disease to a tree with hidden roots. “슬롯 사이트 슬롯사이트 patients face heightened risks for cardiovascular conditions, autoimmune disorders, and emotional distress, underscoring the need for proactive, comprehensive treatment,” he said.
슬롯 사이트 슬롯사이트 has demonstrated superior efficacy across multiple phase 3 trials:
PASI 100 (complete skin clearance at 16 weeks):
※ BE READY: 68.2% (vs. 1.2% placebo, p<0.0001)
※ BE SURE: 60.8% (vs. 23.9% Humira, p<0.001)
※ BE VIVID: 58.6% (vs. 20.9% Stelara, p<0.0001)
※ BE RADIANT: 61.7% (vs. 48.9% Cosentyx, p<0.001)
IGA 0/1 (clear/almost clear skin at 16 weeks):
※ BE READY: 92.6% (vs. 1.2% placebo, p<0.0001)
In 슬롯 사이트 슬롯사이트n participants, 81.3% achieved PASI 90, and 46.9% reported minimal quality-of-life impact (DLQI 0/1, p=0.007), confirming its effectiveness across diverse groups and challenging treatment areas.
Ho-jin Lee, Medical Director at UCB Korea, explained, “Bimzelx, as a dual inhibitor, can be particularly effective in tissues where IL-17F levels are more than 30 times higher than IL-17A, such as in 슬롯 사이트 슬롯사이트 lesions. Since IL-17 plays a role in both IL-23-dependent and IL-23-independent inflammatory pathways, Bimzelx’s ability to block these pathways more comprehensively enables more effective treatment outcomes.”
He added, “In phase 3 clinical trials, Bimzelx demonstrated superior efficacy in difficult-to-treat areas and showed significant results regardless of patients’ prior exposure to biologics or their type. Despite the availability of various 슬롯 사이트 슬롯사이트 treatments, unmet medical needs persist. Bimzelx is expected to provide a valuable new option for 슬롯 사이트 슬롯사이트 patients in Korea.”
The company also confirmed that discussions with health authorities are underway to include Bimzelx under national health insurance for the treatment of plaque 슬롯 사이트 슬롯사이트. Furthermore, efforts are ongoing to expand its indications in Korea to match those approved in Europe, which include psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa.